Sana Biotechnology (NASDAQ:SANA) Upgraded at TD Cowen

TD Cowen upgraded shares of Sana Biotechnology (NASDAQ:SANA - Free Report) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning, Marketbeat.com reports.

A number of other equities analysts also recently commented on the company. JMP Securities downgraded Sana Biotechnology from an "outperform" rating to a "market perform" rating in a research note on Tuesday, November 5th. HC Wainwright restated a "buy" rating and set a $8.00 price objective on shares of Sana Biotechnology in a research report on Wednesday, November 27th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Sana Biotechnology has an average rating of "Moderate Buy" and a consensus target price of $14.25.

Sana Biotechnology Price Performance

SANA traded up $2.65 during trading hours on Wednesday, hitting $4.30. 160,452,780 shares of the stock were exchanged, compared to its average volume of 38,752,840. The stock has a market cap of $960.06 million, a price-to-earnings ratio of -3.07 and a beta of 1.45. The stock has a 50-day simple moving average of $2.39 and a 200-day simple moving average of $4.07. Sana Biotechnology has a 12 month low of $1.52 and a 12 month high of $12.00.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.01. Sell-side analysts expect that Sana Biotechnology will post -1.16 EPS for the current year.

Institutional Investors Weigh In On Sana Biotechnology

A number of hedge funds have recently made changes to their positions in SANA. Bank of New York Mellon Corp increased its position in Sana Biotechnology by 26.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 431,744 shares of the company's stock valued at $2,357,000 after acquiring an additional 90,423 shares during the period. Rhumbline Advisers grew its stake in shares of Sana Biotechnology by 16.0% in the second quarter. Rhumbline Advisers now owns 181,903 shares of the company's stock worth $993,000 after purchasing an additional 25,056 shares in the last quarter. Arizona State Retirement System increased its holdings in shares of Sana Biotechnology by 36.7% during the second quarter. Arizona State Retirement System now owns 37,028 shares of the company's stock valued at $202,000 after purchasing an additional 9,940 shares during the period. XTX Topco Ltd bought a new stake in shares of Sana Biotechnology during the second quarter valued at about $100,000. Finally, Ensign Peak Advisors Inc bought a new stake in shares of Sana Biotechnology during the second quarter valued at about $372,000. Institutional investors own 88.23% of the company's stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.